DK200501310A - The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults - Google Patents
The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults Download PDFInfo
- Publication number
- DK200501310A DK200501310A DK200501310A DKPA200501310A DK200501310A DK 200501310 A DK200501310 A DK 200501310A DK 200501310 A DK200501310 A DK 200501310A DK PA200501310 A DKPA200501310 A DK PA200501310A DK 200501310 A DK200501310 A DK 200501310A
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- diabetes
- adults
- antagonist
- prevention
- Prior art date
Links
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 title description 5
- 208000023275 Autoimmune disease Diseases 0.000 title description 4
- 230000002265 prevention Effects 0.000 title 1
- 239000005557 antagonist Substances 0.000 description 17
- 230000028993 immune response Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 208000001921 latent autoimmune diabetes in adults Diseases 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 2
- 102100038803 Somatotropin Human genes 0.000 description 2
- 230000003178 anti-diabetic effect Effects 0.000 description 2
- 239000000883 anti-obesity agent Substances 0.000 description 2
- 229940030600 antihypertensive agent Drugs 0.000 description 2
- 239000002220 antihypertensive agent Substances 0.000 description 2
- 229940125710 antiobesity agent Drugs 0.000 description 2
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 229940126904 hypoglycaemic agent Drugs 0.000 description 2
- 210000004153 islets of langerhan Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 150000001467 thiazolidinediones Chemical class 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 1
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 1
- 229940045513 CTLA4 antagonist Drugs 0.000 description 1
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 description 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 101800001586 Ghrelin Proteins 0.000 description 1
- 102400000442 Ghrelin-28 Human genes 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 1
- 108010019598 Liraglutide Proteins 0.000 description 1
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 description 1
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 description 1
- 229960002701 liraglutide Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
CLAIMS 1. Use of an IL-21 antagonist for the manufacture of a medicament for the treatment of latent autoimmune diabetes in adults. 2. Use of an IL-21 antagonist for the manufacture of a medicament for prolonging the remission phase in patients with newly diagnosed type 1 diabetes. 3. Use of an IL-21 antagonist for the manufacture of a medicament for reducing the secondary failure rate of treatment with orally active hypoglycaemic agents and/or postponing the need for insulin therapy in islet cell antibody (ICA), insulin antibody-, heat shock protein (hsp) 60 antibody- and/or GAD antibody-positive patients with type 2 diabetes; 4. A pharmaceutical composition comprising an IL-21 antagonist in combination with another agent that suppress immune responses and/or promotes the generation of regulatory immune responses. 5. The use of an IL-21 antagonist for the manufacture of a medicament for the treatment of autoimmune diseases administered in combination with another agent that suppress immune responses and/or promotes the generation of regulatory immune responses 6. The use according to claim 5 wherein the autoimmune diseases are Type 1 Diabetes and LADA. 7. The use according to claim 5 wherein the compounds that suppress immune responses and/or promote regulatory immune responses are CD3 antagonists, hereunder OKT3, CD25 antagonists, CTLA-4 agonists, IL-2 antagonists, IL-2R antagonists, thiazolidin-diones (TZDs). 8. The use of an IL-21 antagonist for the manufacture of a medicament for the treatment of autoimmune diseases including T1D and LADA administered in combination with one or more agents that stimulates the regeneration or neoformation of β-cells, 9. The use according to claim 8 wherein the compounds that promote regeneration and/or neoformation of β-cells are selected from gastrin, gastrin analogues, epidermal growth factor (EGF), EGF-R agonists, fibroblast growth factor (FGF), FGF-R agonists, Keratinocyte growth factor, growth hormone (GH), Ghrelin, glucagon-like peptide (GLP)-1, GLP-1 analogues, hereunder Liraglutide; 10. The use of an? One or more? antagonist of IL-21 for the manufacture of a medicament for the treatment of complications and disorders resulting from or associated with obesity administered together with one or more antidiabetics, antiobesity agents, antihypertensive agents, and/or agents for the treatment of complications resulting from or associated with diabetes. 11. A pharmaceutical composition comprising an antagonist of IL-21 together with one or more compounds that suppress immune responses and/or promote regulatory immune responses. 12. A pharmaceutical composition comprising an antagonist of IL-21 together with one or more agents that stimulate the regeneration or neoformation of β-cells. 13. A pharmaceutical composition comprising an antagonist of IL-21 together with antidiabetics, antiobesity agents, antihypertensive agents, and/or agents for the treatment of complications resulting from or associated with diabetes. 14. A method for the treatment of latent autoimmune diabetes in the adults by administering an effective amount of an antagonist of IL-21; 15. A method for prolonging the remission phase in patients with newly diagnosed type 1 diabetes by administering an effective amount of an antagonist of IL-21; 16. A method for reducing the secondary failure rate of treatment with orally active hypoglycaemic agents and/or postponing the need for insulin therapy in islet cell antibody (ICA), insulin antibody, heat shock protein (hsp) 60 antibody and/or GAD antibody positive patients with type 2 diabetes by administering an effective amount of an antagonist of IL-21.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200501310A DK200501310A (da) | 2005-09-21 | 2005-09-21 | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DK200501310A DK200501310A (da) | 2005-09-21 | 2005-09-21 | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK200501310A true DK200501310A (da) | 2005-10-01 |
Family
ID=35229545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200501310A DK200501310A (da) | 2005-09-21 | 2005-09-21 | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults |
Country Status (1)
| Country | Link |
|---|---|
| DK (1) | DK200501310A (da) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010055366A3 (en) * | 2007-12-07 | 2010-10-21 | Zymogenetics, Inc. | Anti-human il-21 monoclonal antibodies |
| US9388241B2 (en) | 2005-11-28 | 2016-07-12 | Zymogenetics, Inc. | Anti-human IL-21 antibodies |
-
2005
- 2005-09-21 DK DK200501310A patent/DK200501310A/da not_active Application Discontinuation
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9388241B2 (en) | 2005-11-28 | 2016-07-12 | Zymogenetics, Inc. | Anti-human IL-21 antibodies |
| WO2010055366A3 (en) * | 2007-12-07 | 2010-10-21 | Zymogenetics, Inc. | Anti-human il-21 monoclonal antibodies |
| EP2426146A3 (en) * | 2007-12-07 | 2012-05-30 | ZymoGenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| US8226948B1 (en) | 2007-12-07 | 2012-07-24 | Zymogenetics, Inc. | Anti-human IL-21 monoclonal antibodies |
| US8361470B2 (en) | 2007-12-07 | 2013-01-29 | Zymogenetics, Inc. | Methods of treatment using anti-human IL-21 monoclonal antibodies |
| EP3103813A1 (en) * | 2007-12-07 | 2016-12-14 | ZymoGenetics, Inc. | Anti-human il-21 monoclonal antibodies |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI842722B (zh) | 使用gip/glp1共促效劑之療法 | |
| Abasheva et al. | GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity | |
| RU2015101826A (ru) | Применение долгодействующих пептидов glp-1 | |
| EP1515749B1 (en) | Combined use of a modulator of cd3 and a glp-1 compound | |
| KR20200131812A (ko) | 대사 질병을 치료하기 위한 조성물 및 방법 | |
| Kurtzhals et al. | The role of weight control in the management of type 2 diabetes mellitus: perspectives on semaglutide | |
| Cariou et al. | Liraglutide in whole-pancreas transplant patients with impaired glucose homoeostasis: A case series | |
| DK200501310A (da) | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults | |
| JP2025000798A (ja) | 高インシュリン血症性低血糖症の治療のためのアベキシド | |
| CA2666846C (en) | Method of restoring the incretin effect | |
| Gallwitz | GLP-1 Receptor Agonists in Type 2 Diabetes and Beyond–New Insights 2015 | |
| Lim | Commentary on | |
| Chaplin | Semaglutide: a new GLP‐1 analogue for type 2 diabetes | |
| US20250170091A1 (en) | Uses of selective androgen receptor modulator (sarm) compounds in chronic weight management | |
| Brzdęk et al. | Triple agonists of GIP, GLP-1, and glucagon-the future of obesity treatment: a review of the latest findings | |
| WO2024243243A1 (en) | Treatment of adults with overweight or obesity with or without weight-related comorbidities | |
| Repas | Next-generation GLP-1 therapy: an introduction to liraglutide | |
| 板東浩 | Latest Topics on Pharmacotherapy for Obesity Including Glucagon Like Peptide-1receptor Agonists (GLP-1RAs) | |
| Smyth et al. | trials tell us?[version 1; peer review: 2 approved] | |
| WO2024261580A1 (en) | Glp-1 analog for use in the treatment of metabolic disorders | |
| JP2023518645A (ja) | Ｇｌｐ－１の投薬レジメン | |
| JP2023510523A (ja) | 慢性腎疾患及び２型糖尿病における糖尿病性腎疾患の治療のためのグルカゴン及びｇｌｐ－１コアゴニスト | |
| Gadsby | Using insulin earlier in the treatment of type 2 diabetes | |
| Sullivan | Liraglutide looking good in type 2 diabetes | |
| Reutens et al. | Sitagliptin for the management of type 2 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHS | Application shelved for other reasons than non-payment |